Transmission of lupus anticoagulant by allogeneic stem cell transplantation

Abstract

Passive transmission of autoimmune diseases by allogeneic stem cell transplantation is rare and is ascribed to passive transfer of memory B-cells from donor to recipient. We hereby report a case of transmission of an asymptomatic lupus anticoagulant from a sibling donor to a recipient of transplantation for secondary acute myeloid leukemia. On pre-harvest evaluation, the sibling donor with no history of bleeding or thrombosis was found to have a lupus anticoagulant. After engraftment, the recipient was found to have a new prolonged activated partial thromboplastin time and was subsequently shown to have a lupus anticoagulant on Day +73 after stem cell transplantation. The recipient remained well with no evidence of bleeding, thrombosis, or graft-versus-host disease and was on a stable dose of tacrolimus at the time the lupus anticoagulant was detected. There was no other identifiable trigger for the appearance of a lupus anticoagulant.

The use of mesenchymal stem cells in the process of treatment and tissue regeneration after recovery in patients with Covid-19

“…Mesenchymal stem cells, in addition to their immunomodulatory effects, contribute significantly to the regeneration of neurons and synaptogenesis. Some studies have also noted the anticoagulant effects of mesenchymal stem cells (Massoud et al, 2014).…”

Immune-Mediated Complications after Hematopoietic Stem Cell Transplantation

“…Adoptive transfer of autoantibodies and donor lymphocytes during HSCT is theorized to cause autoimmune-like diseases in the recipient, such as new-onset psoriasis, celiac disease, vitiligo, type 1 diabetes, myasthenia gravis (MG), Crohn's disease, and thyroid disease [10,[24][25][26]. However, there are multiple case reports describing recipients who did not develop immune-mediated diseases, despite receiving transplants from donors with known autoimmune disease [27,28].…”